USPTO serial 79348994
NEURACTHEL
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 9, 2024
- Examiner
- KING, LINDA M
- Law office
- Historical data usage
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with NEURACTHEL?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Mark M. Friedman
Mark M. Friedman Dr. Mark Friedman Ltd.7 Jabotinsky St.Moshe Aviv Tower, 54th FlRamat Gan, 5252007Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 003 | Non-medicated cosmetics; cosmetics for protecting against light and UV; cosmetics, namely, cosmetic products as leave-on, lotions, creams, ointments and other formulations as well as cosmetic products for topical use; non-medicated *skin care* preparations for protecting the skin against light and UV; non-medicated skin *care* photoprotection preparations; *non-medicated* sun care preparations for cosmetic use; sun-tanning preparations; *cosmetic* suntan lotions; suntan oils *for cosmetic purposes;* tanning gels; cosmetic preparations for skin care containing analogues of melanocyte stimulating hormone (MSH), in particular afamelanotide; cosmetics for tanning the skin containing analogues of melanocyte stimulating hormone (MSH), in particular afamelanotide; cosmetic preparations for tanning the skin without sunlight containing analogues of melanocyte stimulating hormone (MSH), in particular afamelanotide; sun screen preparations; cosmetic preparations for protecting the skin from the sun's rays; cosmetics for protecting the skin from sunburn; sun protecting creams; sun *block preparations;* sun block; sun blocking preparations; sun-block lotions; sun blocking oils; SPF sun block sprays; *lip balm with sun block;* sun blocking lipsticks; *cosmetic sunscreen preparations;* waterproof sunscreen *preparations;* water-resistant sunscreen *preparations;* sunscreen preparations; sunscreen creams; sunscreen lotions; sunscreen sticks; cosmetic foams containing sunscreen *preparations; sunscreen* preparations for protecting the hair from the sun; *nonmedicated cosmetic preparations against sunburns;* non-medicated *sun care preparations* for skin care after exposure to the sun's rays. | ACTIVE | — |
| 005 | Pharmaceuticals *for the prevention and treatment of neurological, endocrinological, and degenerative disorders;* pharmaceutical drugs *for the prevention and treatment of epidermal problems, and damaged skin and tissue;* pharmaceutical products for endocrine, neuroendocrine, systemic, inflammatory, and acute disorders such as sepsis, shock, haemorrhagic shock, acute bleeding disorders, and chronic disorders requiring prevention, curative or palliative treatment where no other treatments are effective or safe; pharmaceutical preparations *for the prevention and treatment of viral, metabolic, genetic, endocrine, musculoskeletal, ophthalmic, cardiovascular, cerebrovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, and immune system related diseases and disorders;* pharmaceuticals used for cerebrovascular accidents *in the nature of strokes*; pharmaceutical preparations for the prevention and treatment of arterial ischemic strokes; medicines for the treatment of cardiovascular and cerebrovascular diseases; pharmaceutical preparations for the prevention and treatment of cardiovascular and cerebrovascular diseases; cardiovascular drugs for use in treating hypertension; cardiovascular preparations *for the prevention and treatment of cardiometabolic conditions;* cardiovascular pharmaceuticals *for the prevention and treatment of ischemic syndromes;* cardiovascular pharmaceutical preparations *for the prevention and treatment of cardiomyopathies;* cardiovascular agents for medical purposes; cardiovascular drugs used in treating *cardiogenic shocks;* cardiovascular drugs used in myocardial infarctions; cardiovascular drugs used in treating arrhythmias; cardiovascular drugs used in angina pectoris; cardiovascular drugs used in treating congestive heart failure (CHF); pharmaceutical preparations containing analogues of melanocyte stimulating hormone (MSH), in particular afamelanotide; medicated sun care preparations, namely, sun tanning preparations for pharmaceutical purposes containing analogues of melanocyte stimulating hormone (MSH), in particular afamelanotide; pharmaceutical preparations for skin care; pharmaceutical preparations for treating skin disorders; *dermatologicals, namely, dermatological preparations, dermatological pharmaceutical substances, dermatological pharmaceutical products;* medicinal creams for the protection of the skin; skin care creams for medical use; skin care preparations for medical use; medicated skin creams and lotions; medicated *skin care* creams for application after exposure to the sun; pharmaceutical skin lotions; preparations for cleansing the skin for medical use; *medicated chemical and biological skin care preparations and chemical reagents* for medical purposes which contain analogues of melanocyte stimulating hormone (MSH), in particular afamelanotide; *drug afamelanotide in aqueous and gel formulations;* pharmaceutical implants *comprising living tissue;* subcutaneous implants containing *living tissue and also containing* afamelanotide; implantable *subcutaneous drug delivery devices sold filled with pharmaceutical preparations for the prevention and treatment of neurological, endocrinological, and degenerative disorders; implantable subcutaneous drug delivery devices sold filled with pharmaceutical preparations and containing afamelanotide for the prevention and treatment of skin related diseases and disorder* | ACTIVE | — |
| 010 | Medical apparatus, devices and instruments *for accessing subcutaneous structures of the human body for the purpose of administering medical treatment;* apparatus for drug administration, *namely, drug delivery catheters;* devices for use in the administration of pharmaceuticals, namely, implantable drug delivery ports; controlled rate release apparatus for dispensing pharmaceutical substances, *namely, implantable drug delivery pumps;* medical fluid injectors; injection syringes; medical syringes; implantable subcutaneous drug delivery *ports and pumps* | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Clinuvel Europe Ltd
- Other trademarks owned by Clinuvel Europe Ltd
- Other trademarks owned by Clinuvel Europe Ltd
- Other trademarks in Class 003
- Other trademarks in Class 005
- Other trademarks in Class 010
- Similar marks named NEURACTHEL
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 30, 2024 | NURC | NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED | — |
| Jul 14, 2024 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jun 25, 2024 | COC. | CORRECTION UNDER SECTION 7 - PROCESSED | — |
| Jun 25, 2024 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jun 24, 2024 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jun 24, 2024 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Apr 9, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jan 9, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jan 9, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 24, 2023 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Oct 24, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 24, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 4, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Oct 4, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Oct 4, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 15, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 14, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 14, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 14, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 14, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Sep 14, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 14, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Sep 14, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Sep 14, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Apr 20, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 28, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 28, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Feb 2, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Feb 1, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 25, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 13, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 9, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 8, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |